Status In progress
Process STA
ID number 1173

Provisional Schedule

Expected publication 13 March 2019

Project Team

Project lead Kate Moore

Email enquiries


Key events during the development of the guidance:

Date Update
05 April 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer. The appraisal is now anticipated to begin in early May 2018 with submissions anticipated early July 2018.
21 July 2017 This appraisal will be rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
05 December 2016 Referral
05 December 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance